Back to search
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic Atrophy
Macular Degeneration
Clinicaltrials.gov:
EU CTIS:
#2022-500747-21-00
Other:
#81201887MDG3002
Interested in this trial?
Email or download this trial
Trials at a glance
Status
Enrolling
Condition
Geographic Atrophy
Macular Degeneration
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
JNJ-81201887
Sham Procedure
Age
60+ years old
Biological sex
All
Placebo?
No
Trial start date
September 19, 2024
Trial end date
June 27, 2030
CT.gov ID
#NCT06635148
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to assess the long-term safety and tolerability after an
intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in
parent clinical studies.
Primary outcome measures
- Number of Participants with Ocular and Systemic Treatment-emergent Adverse Events (TEAEs)
- Number of Participants with Abnormal Findings in Clinical Laboratory Assessments
- Number of Participants with Abnormal Findings in Retinal imaging and Eye Examinations
Access detailed
information on the trial:
information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2025
